# Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

> **NCT00514514** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 802 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Myfortic
- **DRUG:** Sandimmun Optoral
- **DRUG:** Simulect®

## Key facts

- **NCT ID:** NCT00514514
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514514, "Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00514514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*